Drug Profile
Tesmilifene
Alternative Names: DPPE; YMB-1002Latest Information Update: 11 Mar 2014
Price :
$50
*
At a glance
- Originator CancerCare Manitoba; University of Manitoba
- Developer Shin Poong Pharmaceutical; YM BioSciences
- Class Antineoplastics; Phenyl ethers; Small molecules
- Mechanism of Action Estrogen receptor antagonists; Histamine receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Gastric cancer; Prostate cancer
Most Recent Events
- 02 Feb 2007 YM BioSciences terminates a worldwide pivotal phase III trial (DEC) in advanced Breast cancer
- 21 Dec 2006 YM Biosciences and TTY Biopharm agree to co-develop tesmilifene for Liver cancer in Taiwan
- 05 Jun 2006 Phase-II clinical trials in combination with docetaxel in patients with metastatic Breast Cancer in Europe and USA (IV)